Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will discuss strategies for funding RNA-based cell therapies as a panel member at the RNA Cell Therapies Summit. The panel discussion, “The Science Speaks for Itself – But What Else is Required to Secure an Investment,” will include both medical and venture capital experts. Panelists will reveal what investors look for when investing in RNA-based cell therapies and share insights into how best to work holistically with scientists, investors, and lawyers to secure investments. Discussion will also include the role a founders legacy plays in investment opportunities.
With experience as CEO and CMO of multiple pharmaceutical and biotechnology companies and C-suite advisor for several early-stage biotechnology companies, Dr. Fiore is uniquely qualified to provide his expert knowledge in raising capital to advance new therapeutics.
“While scientific discovery is vital to the development of novel treatment options, securing financial support is a critical requirement in progressing new therapeutics all the way through to patient delivery,” said Dr. Fiore.
The panel will take place at 2:30 pm ET on Thursday, January 26, 2023.
The RNA Cell Therapies Summit will take place January 24-26, in Boston. The meeting will focus on specific challenges associated with RNA cell therapy development and how to accelerate these promising therapies through the value chain.
About Exacis Biotherapeutics
Exacis is a development stage immuno-oncology company focused on harnessing the human immune system to cure cancer by engineering next generation off-the-shelf NK and T cell therapies aimed at hematologic malignancies and solid tumors. Exacis was founded in 2020 with an exclusive global license to a broad suite of patents covering the use of mRNA based cell reprogramming and gene editing technologies for use in generating engineered NK and T cells for oncology applications.
Exacis’ approach avoids the use of DNA and viruses and instead uses a proprietary mRNA based technology. Exacis uses the technology to generate iPSCs and to edit their genome to create stealthed, performance enhanced allogeneic NK and T cell products, termed ExaNK™, ExaCAR-NK™ and ExaCAR-T™ cells.
About T and Natural Killer (NK) Cell Therapies
T and NK cells are types of human immune cells that are able to recognize and destroy cancer cells and can be modified through genetic engineering to target and kill specific tumors.
Contact Exacis Biotherapeutics for further information and media: